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Hypercalcaemia in cats 
 
 
 
Abstract 
Practical relevance: Calcium is essential for many normal physiological processes 
within the body. Hypercalcaemia can therefore result in clinical signs such as 
polyuria and polydipsia, lethargy and weakness due to depressed excitability of 
muscle and nervous tissue and gastrointestinal (GI) signs due to effects on GI 
smooth muscle. The most common causes of hypercalcaemia in cats are 
idiopathic, chronic kidney disease and neoplasia.  
 
Clinical challenges: Hypercalcaemia can be a diagnostic challenge and a good 
understanding of the regulation of calcium homeostasis can aid in interpreting 
results. Furthermore, the management approach may depend on the underlying 
cause of hypercalcaemia and also its severity and chronicity. 
 
Audience: This review offers a comprehensive discussion of the regulation of 
calcium homeostasis with a focus on the normal response to hypercalcaemia. It 
also discusses the diagnostic approach, management and specific aetiologies of 
hypercalcaemia in cats. This is relevant to all clinicians working with feline 
patients. 
 
Evidence base: The review draws evidence from peer-reviewed publications and 
also the author’s own clinical experience. 
 
Calcium function and homeostasis 
Calcium plays a key role in many normal physiological processes. It is important 
in neuromuscular transmission, enzyme activity, blood coagulation, muscle 
contraction (including skeletal, smooth and cardiac muscle) and is required for 
intracellular signalling and normal cellular function. Calcium also regulates 
vascular smooth muscle tone and hence blood pressure. It is the most abundant 
component of the skeleton being required for both new bone formation and 
resorption and in maintaining structural integrity of bones and teeth.  
Regulation of calcium is complex. It is generally accepted that parathyroid 
hormone (PTH) is responsible for the minute-to-minute control of calcium, 
calcitriol for the day-to-day control and calcitonin having a relatively minor role 
in its regulation in the adult. The three organ systems responsible for calcium 
homeostasis include the gastrointestinal (GI) tract, kidneys and bone. PTH 
increases calcium reabsorption in the distal convoluted tubules of the kidney and 
decreases phosphate reabsorption from the proximal tubules resulting in 
reduced calcium and increased phosphate excretion in urine. It is reported that 
approximately 98-99% of filtered calcium is reabsorbed in the kidneys of normal 
human patients1 with the predominant site of reabsorption being the proximal 
tubules. PTH also stimulates osteoclastic bone resorption and increases the 
number of osteoclasts on the bone surface to release calcium and phosphate 
from bone. Calcitriol (1,25 dihydroxycholecalciferol), otherwise known as the 
active form of vitamin D, increases the absorption of calcium and phosphate 
from the GI tract and reabsorption in the renal tubules. Intestinal absorption of 
calcium is via an active transport process in the duodenum.2 A calcium pump 
system transports calcium from the mucosa into blood. Transport of calcium 
across the enterocyte requires the carrier protein calbindin that is vitamin D 
dependent. If diet is low in calcium then this pump system becomes more active 
and if dietary calcium is high, the pump system becomes less active. Passive 
diffusion of calcium across the enterocyte can also occur at high concentrations 
of calcium in the jejunum and ilium and to a lesser extent in the colon.2 However, 
it has been suggested that calcium absorption is unaffected by calcium intake 
and that mechanisms other than GI absorption are more important for its 
homeostasis in the short term in cats and dogs.3 Calcitonin is a potent calcium 
lowering hormone and acts predominantly on bone to inhibit osteoclastic bone 
resorption. The terms reabsorption and resorption may be easily confused. 
Within this review they are used to describe the process of absorbing a 
substance again and the process of losing a substance (s) from bone respectively. 
 
Figure 1: Regulation of calcium homeostasis in the body 
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Figure 2: Relationship between calcium and its homeostatic regulators. Bold line 
indicates a positive (stimulatory) relationship and dashed line indicates a 
negative (inhibitory) relationship. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PTH is produced from chief cells in the parathyroid gland in response to ionised 
hypocalcaemia. Its actions to increase renal tubular reabsorption of calcium, 
increase bone resorption and increase calcitriol production in the kidneys, 
results in a net effect of increasing ionised calcium concentration. Calcitriol is 
produced in the kidneys and increases calcium absorption in the GI tract, and 
reabsorption in the renal tubules and enhances the ability of PTH for bone 
resorption. Therefore, the net effect is also to increase ionised calcium 
concentration. Cats have low levels of vitamin D in their skin and it is not 
synthesised in the skin in response to sunlight as in humans.4 Therefore, cats are 
dependent on dietary intake and it is often supplemented in pet foods. It is 
important to remember that PTH and calcitriol are also influenced by phosphate 
concentrations. Calcitonin is secreted from C cells in the thyroid gland in 
response to hypercalcaemia. Calcitonin inhibits osteoclastic activity that 
decreases bone resorption. It can also increase renal excretion of both calcium 
and phosphate. GI hormones such as gastrin can stimulate the secretion of 
calcitonin2 and this mechanism is considered to help regulate postprandial 
hypercalcaemia.  
 
Physiological response to hypercalcaemia 
The normal physiological response to hypercalcaemia includes decreased 
production of PTH from the parathyroid gland, increased production of 
calcitonin from C cells in the thyroid gland and decreased calcitriol production in 
PTH 
Calcium 
Calcitriol 
Calcitonin 
the kidneys due to direct inhibition and also decreased PTH production. This 
results in: 
1) Reduced release of calcium and phosphate from bone due to reduced PTH 
concentrations 
2) Increased renal excretion of calcium due to decreased PTH and calcitriol 
concentrations 
3) Decreased intestinal absorption of calcium due to decreased calcitriol 
concentration. 
The relationship between calcitropic hormones and calcium can be evaluated 
further by examining the PTH-calcium and calcitonin-calcium curves (see 
Figures 3 and 4). When examining the calcitonin-calcium curve, it can be seen 
that there is a group of cats that do not increase their calcitonin concentration in 
response to hypercalcaemia. This group has been termed ‘non-responders’.5 This 
recent finding may suggest that certain cats are unable to evoke a normal 
physiological response in the face of hypercalcaemia to increase calcitonin and 
hence decrease ionised calcium concentration.  
 
Figure 3: PTH-calcium curve. PTH concentration decreases in response to 
increasing ionised calcium concentration. I-PTH is intact PTH and W-PTH is 
whole PTH. Taken from6 
 
 
 
Figure 4: Calcitonin-calcium curve. Bold line represents the group of cats in 
which calcitonin concentration increases in response to increasing ionised 
calcium – that is the expected response. The dashed line represents a second 
group of cats that do not increase their calcitonin concentration in response to 
hypercalcaemia. Taken from5  
 
 
 
Identification of hypercalcaemia and implementation of appropriate therapy is 
important as it may lead to development of soft tissue calcification (especially in 
cardiac and skeletal muscle, stomach and kidneys). Mineralisation of renal tissue 
may result in nephron injury or changes in renal blood flow causing a decline in 
renal function and azotaemia. Hypercalcaemia may promote formation of 
calcium oxalate uroliths that can lead to urinary tract obstruction. Whether acute 
hypercalcaemia induces pancreatitis remains controversial. Early studies 
examining the effects of calcium administration on the pancreas of cats identified 
necrosis of pancreatic acinar7, 8 and ductal cells8 after 12hrs of IV calcium 
infusion suggesting hypercalcaemia may play a role in pancreatitis. 
 
Measurement of calcium 
Approximately 99% of total body calcium is stored in bones in the form of 
hydroxyapatite crystals.9 These crystals contain calcium, phosphate and water 
and can act as a reservoir to release calcium when extracellular calcium 
concentration declines. Calcium can also be found intracellularly and is 
important in normal cellular function. The smallest pool of calcium in the body is 
found in the extracellular space. This includes calcium in the blood, interstitium 
and accessible bone-calcium pool. It is calcium in the extracellular space that is 
measured in the clinical patient. Extracellular calcium exists in 3 fractions:- 
1) Ionised calcium. This is the largest fraction considered to be 
approximately 52% of total calcium in normal cats.10 It is the biologically 
active form of calcium. 
2) Complexed calcium. This is the smallest fraction considered to be 
approximately 8% of total calcium in normal cats.10 It can be complexed 
with anions such as phosphate, lactate or bicarbonate. 
3) Protein bound calcium. Approximately 40% of total calcium is considered 
to be protein bound.10 
 
It is important when collecting a blood sample for measurement of calcium not 
to transfer the sample into a tube containing anticoagulant. This is because the 
anticoagulant will chelate calcium and artificially decrease its concentrations. 
Results for ionised calcium are also lower in heparinised blood samples 
compared to serum samples so cannot be directly compared.11 The age of the cat 
will also affect calcium concentration. Plasma calcium has been reported to be 
higher in young animals along growth phases due to increased bone turnover. In 
particular kittens will have increased concentrations and both total and ionised 
calcium concentration can remain increased until 12 months of age (see figure 
5).12  
 
Figure 5: Total and ionised calcium in growing cats. Taken from12 
 
 
 
Adjustment formulas to correct total calcium for the albumin or total protein 
concentration are not recommended. Moreover, it is not possible to accurately 
predict ionised calcium from total calcium. In one study total calcium was 
inaccurate in predicting ionised calcium in 40% of cats with the prevalence of 
hypercalcaemia and normocalcaemia being underestimated and hypocalcaemia 
being overestimated.10 
Ionised calcium concentration must be measured to accurately assess the 
calcium status. Analysis with ion-selective electrodes is required for measuring 
ionised calcium (See Figure 6). Samples should be collected anaerobically if 
analysis cannot be performed immediately. Exposure to air will lead to loss of 
CO2, which increases pH and consequently increases calcium binding to protein 
and results in decreased ionised calcium concentration. The converse of this is 
important in acidaemic patients in which hydrogen ions will displace protein 
bound calcium ions and increase ionised calcium concentration. If in-house 
analysis of ionised calcium is not possible, samples will need to be transported to 
a reference laboratory on ice and submission of the sample should be discussed 
with the laboratory prior to collection. 
 
Figure 6: Ion-selective electrode analysers should be used for the measurement 
of ionised calcium. 
 
 
 
Clinical signs 
The clinical signs (see box 1) of hypercalcaemia in cats can be vague and non-
specific, and are often not noticed by owners. Polyuria and polydipsia (PU/PD) 
resulting from a nephrogenic diabetes insipidus is common and can also be 
secondary to renal damage. Lethargy and weakness may result from depressed 
excitability of muscular and nervous tissue. Anorexia, vomiting and constipation 
may be a consequence of decreased contractility of the smooth muscle in the GI 
tract. Muscle twitching and potentially development of seizure activity may be 
seen due to direct effects of hypercalcaemia on the central nervous system. 
Cardiac arrhythmias can also develop due to direct effects on cardiac tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
Differential diagnoses 
Box 2 lists the differential diagnoses for hypercalcaemia in cats. The most 
common causes are idiopathic,13 CKD14 and neoplasia.14 Non-pathological causes 
Box 1: Common clinical signs associated with 
hypercalcaemia in cats 
 Polyuria and polydipsia 
 Lethargy/ weakness 
 Anorexia 
 Vomiting  
 Constipation 
 Muscle twitching 
 Cardiac arrhythmias 
that should be considered when interpreting results include non-fasted 
sampling, hyperlipidaemia, hyperproteinaemia, haemoconcentration, laboratory 
error and physiological growth in young animals. Hypoadrenocorticism and 
primary hyperparathyroidism are very rare in cats with one study reporting 
primary hyperparathyroidism in only 6% and hypoadrenocorticism in only 1% 
of hypercalcaemic cats.14 Hyperthyroidism is generally associated with ionised 
hypocalcaemia; however, cases of hypercalcaemia have been reported.15 This 
may be associated with underlying CKD.16 Excessive calcium supplementation 
for example calcium containing intestinal phosphate binders may theoretically 
contribute to hypercalcaemia although this remains unreported in clinical cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostic approach 
 
Blood testing 
Biochemistry 
Measurement of ionised calcium should be performed to confirm 
hypercalcaemia if total calcium is elevated. Hypercalcaemia should also be 
demonstrated to be persistent. Full biochemistry should be performed ensuring 
the panel includes assessment of renal function and phosphate concentration. If 
available, acid-base analysis should also be performed.  
 
PTH 
One useful approach is to assess if the hypercalcaemia is parathyroid dependent 
(i.e. arising from the parathyroid gland) or parathyroid independent. This is 
achieved by measuring PTH. The majority of cats will have parathyroid 
independent hypercalcaemia. Indeed, in one study only 8.4% of hypercalcaemic 
cats were reported to have parathyroid dependent hypercalcaemia.17 In normal 
patients, PTH production from the PTH glands will be supressed in response to 
hypercalcaemia. Therefore, if PTH concentration is in the upper 2/3 of the 
reference interval or is increased, it suggests a parathyroid dependent cause. 
Caution should be taken in interpreting results of PTH assays. Appropriate 
sample handling must be strictly adhered to as PTH is relatively heat labile, 
which can affect results. Samples must be shipped on ice and the commercial 
laboratory to which the sample is to be submitted should be contacted to discuss 
sample transport. Feline PTH is 84% homologous to human PTH.18 This is 
important because assays used to measure PTH in cats are human assays. There 
Box 2: Differential diagnoses for hypercalcaemia 
in cats 
 Idiopathic 
 CKD/renal failure 
 Neoplasia – malignancy associated 
 Hypervitaminosis D 
 Granulomatous disease 
 Primary hyperparathyroidism 
 Hypoadrenocorticism 
 
are different assays available for measuring PTH. The second-generation (intact) 
PTH assays measure intact PTH (1-84) and also PTH (7-84) fragment. C-PTH 
fragments can accumulate in kidney disease, which may result in falsely elevated 
results. The third-generation whole PTH assays do not measure the fragments. 
Earlier studies validating PTH measurement in cats utilised intact PTH assays 
that are no longer commercially available.19, 20 A recent study in cats validating 
newer human intact PTH and whole PTH assays found greater whole PTH 
concentrations compared to intact PTH.6 This was thought to be related to 
reduced affinity of the antibody (which was developed for use with human 
samples) utilised in the assay against feline PTH. Considering the variable results 
obtained with different assays, it is important to discuss with the laboratory to 
which the sample is to be submitted, which assay is being used and whether 
appropriate validation and reference intervals have been established in the 
laboratory for the assay. 
 
Parathyroid hormone related peptide (PTH-rp)  
PTH-rp can be measured if malignancy is suspected but can be normal and 
therefore, a normal value does not fully exclude neoplasia.17 
 
Vitamin D metabolites 
1,25 dihydroxyvitamin D3 (calcitriol) and 25 hydroxyvitamin D3 (calcidiol) can 
be measured. Calcitriol reflects metabolically active vitamin D and calcidiol 
reflects cholecalciferol or ergocalciferol ingestion. Calcidiol is the major 
circulating form of vitamin D. Vitamin D metabolites are identical in all species 
and therefore, the performance of assays used to measure vitamin D is better 
than for those used to measure PTH. Samples should be protected from light to 
inhibit degradation.  
 
Urinalysis 
Increased excretion of calcium in the urine of cats that are hypercalcaemic can 
predispose them to calcium oxalate urolith formation. Uroliths were identified in 
15% of hypercalcaemic cats in a retrospective study of which 73% were 
composed of calcium oxalate.14 
 
Diagnostic imaging 
Thoracic and abdominal imaging can be helpful in screening for neoplasia or 
granulomatous lesions. Soft tissue calcification can occur when the calcium x 
phosphate product is >5.6mmol/l. The kidneys and gastric mucosa are the 
predominant organs to be affected and this may be visualised on radiographs or 
CT imaging (see figure 7). Radiographs may also identify calcium oxalate 
nephroliths, ureteroliths or cystoliths. If primary hyperparathyroidism is 
suspected (which, as discussed above, is rare in cats), cervical ultrasonography 
can be performed to attempt to visualise a parathyroid mass, although, this 
requires some expertise. 
 
Figure 7: Transverse CT image of cranial abdomen and caudal thorax. A 
mineralised gastric wall that was identified in a hypercalcaemic cat is indicated 
by the red arrow. 
 
  
 
General management 
The management approach will depend on not only the severity of the 
hypercalcaemia but also the time frame of development (i.e. acute versus 
chronic). Patients with mild hypercalcaemia (ionised calcium <0.25mmol/l 
above the reference interval21) which are asymptomatic and have normal 
calcium x phosphate product may require no immediate treatment whereas 
patients with a severe acute rise in calcium concentrations may require more 
aggressive treatment. There is no single treatment that is recommended for 
managing all causes of hypercalcaemia and therefore the underlying cause 
should be addressed. Supportive therapy is aimed at enhancing renal excretion 
of calcium and preventing calcium resorption from bone. Table 1 lists different 
drugs that can be used for the management of hypercalcaemia and their doses. 
Specific management for underlying aetiologies is discussed in the specific 
aetiologies section. 
 
Table 1: Drugs and dosages for use in the management of hypercalcaemic cats 
 
Drug Class of drug Dose Route of 
administration 
Frequency of 
administration 
Furosemide Diuretic 1-2 
mg/kg 
IV, SC, PO BID to TID 
Prednisolone Glucocorticoid 0.5-1 
mg/kg 
PO SID to BID 
Dexamethasone Glucocorticoid 0.1-0.2 
mg/kg 
IV, SC SID  
Pamidronate Bisphosphonate 1.0-2.0 
mg/kg 
Slow (approx. 
4hrs) infusion 
in 0.9%NaCl 
May be 
repeated after 
7-14 days 
Alendronate Bisphosphonate 5-20 
mg/cat 
PO Q 7 days 
Calcitonin Endocrine drug 4-6 SC BID to TID 
IU/kg 
 
 
Promoting calciuresis 
Management can include intravenous fluid therapy (IVFT) and furosemide to 
promote calciuresis. It is important a cat is well hydrated before initiating 
furosemide therapy. IVFT can be administered to correct any fluid deficits and 
the associated volume expansion will aid in diluting circulating calcium 
concentrations. Isotonic saline (0.9% NaCl) is the recommended fluid of choice 
as it does not contain calcium. If there is concern regarding a cat’s renal or 
cardiac function, fluid therapy should be approached cautiously as they may be 
susceptible to fluid volume overload given their small size. Furosemide acts to 
inhibit calcium reabsorption in the loop of Henle. Thiazide diuretics should not 
be used as these enhance the reabsorption of calcium in the renal distal tubules.  
 
Glucocorticoids 
Glucocorticoids act to reduce bone resorption, decrease intestinal absorption 
and increase renal excretion of calcium. Their mechanism of action is thought to 
be through inhibiting prostaglandin E, osteoclastic activating factor and vitamin 
D production.22 It is important to avoid steroids if the underlying aetiology 
remains unclear and further investigations to determine a definitive diagnosis 
are to be pursued. 
 
Bisphosphonates 
Bisphosphonates exert their effect by reducing the number and activity of 
osteoclasts. There are few reports of the use of these drugs in cats. Pamidronate 
is available and is administered as an IV infusion. Recently alendronate has been 
evaluated in a small study of cats with idiopathic hypercalcaemia.23 
Approximately 2/3 of the cats included in the study achieved normocalcaemia 
during the 6-month study period and adverse effects were not noted. The 
advantage of alendronate over other bisphosphonates is its oral route of 
administration rather than via an intravenous infusion. In addition, it requires 
only once weekly administration. To optimise GI absorption it is best 
administered after fasting. 
 
Calcitonin 
Although calcitonin is one of the normal physiological regulators in decreasing 
calcium concentration, its effects are short lived requiring multiple daily 
administration and therefore, it does not lend itself to use in clinical patients. In 
dogs it has also been associated with side effects such as anorexia and vomiting 
and development of tolerance to therapy.24 
 
Dietary change 
Dietary change is perhaps one of the most important aspects of management in 
cats with idiopathic hypercalcaemia. High fibre diets can be fed which bind 
intestinal calcium thus reducing its absorption. Wet diets can also be helpful in 
promoting diuresis and are generally associated with lower calcium content than 
dry diets. Feeding a renal diet may be successful in some cases as these are 
formulated to be low in calcium and phosphate concentration and are more 
alkalizing than normal maintenance diets. However, hypercalcaemia has been 
noted in cats fed a renal diet and so this diet should be discontinued if 
hypercalcaemia worsens. Diets formulated for management of calcium oxalate 
urolithiasis may also be considered as these diets are restricted in calcium and 
decrease urinary acidification.  
 
 
Specific aetiologies 
Idiopathic hypercalcaemia 
Idiopathic hypercalcaemia is considered the most common diagnosis in 
hypercalcaemic cats and the cause remains unknown. There may be genetic 
factors or possibly dietary factors. Some studies have reported an association of 
hypercalcaemia with the feeding of an acidifying diet or use of urinary acidifiers 
which resolved after dietary change or discontinuation of the urinary acidifying 
therapy.25 These diets may result in a chronic metabolic acidosis that increases 
bone resorption and hence promotes hypercalcaemia and urinary calcium 
excretion,26,27 although this remains unproven in healthy cats.28 Idiopathic 
hypercalcaemia can be seen in cats of any age and there is no sex predisposition, 
however, longhaired cats appear to be over represented.13 Clinical signs are 
often vague or absent and it may be detected as an incidental finding. In some 
cases calcium may be increased for months without overt clinical signs. If clinical 
signs do develop these may include weight loss, diarrhoea, constipation, 
vomiting or anorexia. In patients with idiopathic hypercalcaemia, the total and 
ionised calcium are elevated but phosphate, PTH-rp and vitamin D metabolites 
are normal. PTH may be normal or decreased due to the suppressive effect of 
hypercalcaemia. The magnitude of hypercalcaemia in affected cases is generally 
mild to moderate. In one retrospective study, 40% of cases with idiopathic 
hypercalcaemia were reported to have mild total hypercalcaemia (2.88 – 
3.00mmol/l), 55% had moderate total hypercalcaemia (3.00 – 3.50mmoll) and 
only 5% reported to have severe total hypercalcaemia (>3.50mmol/l).13 Dietary 
change may be successful in many cases and therefore implementing the feeding 
of a high fibre diet, supplementing with psyllium husks or feeding a wet diet is 
recommended as an initial first step, particularly in cases with only mild or 
moderate hypercalcaemia. Feeding a renal diet or diet formulated for 
management of calcium oxalate urolithiasis can be considered as an alternative 
as discussed above. Figure 8 presents an algorithm for the approach to managing 
minimally symptomatic cats with idiopathic hypercalcaemia. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Recommended algorithm for management of minimally symptomatic 
cats with idiopathic hypercalcaemia. The bold arrows indicate the recommended 
approach and the red arrows indicate an alternative approach that can be 
considered. Adapted from21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic kidney disease 
Hypercalcaemia and renal azotaemia can be a difficult diagnostic challenge as 
hypercalcaemia can cause renal failure or develop as a consequence of renal 
failure. The prevalence of hypercalcaemia increases with the severity of 
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azotaemia with one study reporting 8% of cats with early compensated kidney 
disease to have a total hypercalcaemia, 18% of cats with uraemic kidney disease 
and 38% with end stage kidney disease.29 Generally speaking, in cats with early 
and mid stage CKD, ionised calcium is low and total calcium is normal or 
increased. This is the result of increased phosphate concentration associated 
with reduced renal clearance forming complexes with ionised calcium. Indeed, in 
the study reporting total hypercalcaemia with early compensated, uraemic and 
end stage kidney disease, only 0%, 9% and 6% of cats had ionised 
hypercalcaemia for each group respectively.29 This supports the current 
understanding that the total hypercalcaemia that may be seen in CKD is 
generally associated with increased complexed calcium. In late stage CKD 
tertiary hyperparathyroidism can develop from progression of renal secondary 
hyperparathyroidism. This is thought to result from an altered set point of the 
calcium sensing receptor and uncontrolled secretion of PTH from the 
parathyroid gland.  Management of hypercalcaemia in cats with CKD includes 
reducing phosphate retention through feeding a renal diet that is restricted in 
protein and phosphate. Intestinal phosphate binders can also be used. However, 
it important to note that some cats can develop hypercalcaemia when being fed a 
renal diet, although, the reasons for this remain unclear. Some phosphate 
binders contain calcium carbonate that may, theoretically speaking, contribute to 
hypercalcaemia. Some clinicians advocate the use of calcitriol as part of the 
management of CKD in cats. This is considered to be beneficial due to decreased 
calcitriol production in the diseased kidney. Calcitriol will also suppress PTH 
production thus aiding in the management of renal secondary 
hyperparathyroidism. However, there is a significant risk of development of 
hypercalcaemia with its use and no proven clinical benefit and therefore, its use 
is not recommended at this time. It would also be contraindicated in a 
hypercalcaemic patient. 
 
Hyperparathyroidism 
Primary hyperparathyroidism is rare in cats as discussed above. It is associated 
with increased total and ionised calcium concentration, increased PTH 
concentration, decreased phosphate concentration and normal or increased 
calcitriol. If primary hyperparathyroidism is confirmed, the abnormal 
parathyroid tissue can be surgically resected with close monitoring for 
development of hypocalcaemia or recurrent laryngeal nerve damage following 
the surgery. Other alternative management approaches which have been 
reported in dogs include ultrasound guided radiofrequency heat ablation and 
ethanol ablation of the parathyroid gland.30  
Secondary hyperparathyroidism can be classified as nutritional or renal. In 
nutritional hyperparathyroidism it is low calcium or altered calcium: phosphate 
ratio in the diet that stimulates production of PTH. Therefore, it is not generally 
associated with hypercalcaemia. It is something which may be recognised more 
commonly with the increasing popularity of feeding bone and raw food (BARF) 
diets with between 20-60% of such diets being unbalanced in calcium, vitamin D 
and phosphate.2  Nutritional secondary hyperparathyroidism is often associated 
with a predominantly meat diet as these are low in calcium but high in 
phosphate which stimulates PTH production.  
Renal secondary hyperparathyroidism results from reduced renal clearance of 
phosphate in patients with decreased glomerular filtration rate. The increasing 
blood phosphate forms complexes with calcium resulting in a corresponding 
decrease in calcium concentration and stimulating PTH production.  
Tertiary hyperparathyroidism results from autologous secretion of PTH from the 
parathyroid gland and can lead to development of hypercalcaemia. It is rarely 
recognised in cats but can be associated with end stage kidney disease. 
 
 
Malignancy associated hypercalcaemia 
Hypercalcaemia of malignancy is less common in cats than in dogs. Neoplasia as 
the underlying cause was found in approximately 2/3 of hypercalcaemic dogs vs. 
1/3 of hypercalcaemic cats.22 Hypercalcaemia can develop through humoral 
mechanisms or through osteolytic mechanisms. Osteolytic mechanisms can 
include metastatic spread to bone, haematological abnormalities in the bone 
marrow or local production of bone resorbing factors. Primary bone neoplasia is 
rarely associated with hypercalcaemia. In humoral hypercalcaemia of 
malignancy, production of PTH-rp plays an important role in the pathogenesis; 
however, cytokines such as interleukin-1 (IL-1) and transforming growth factor 
–beta (TGF-β) may also play a role.22 Both PTH-rp and cytokines have similar 
functions to PTH to stimulate bone resorption. In cats, squamous cell carcinoma 
and lymphoma would be the two most common neoplasias associated with 
hypercalcaemia accounting for 2/3 of all neoplasia in one retrospective study.14 
Other neoplasias which have been associated with hypercalcaemia in cats 
include multiple myeloma31 bronchocarcinoma14, osteosarcoma14, and 
fibrosarcoma.14 Both total and ionised calcium are increased in patients with 
malignancy associated hypercalcaemia and therefore, PTH concentration should 
be normal or low. PTH-rp can be increased but can also be normal.17 
Management involves specific management of the underlying neoplasia. The use 
of glucocorticoids prior to confirmation of the diagnosis should be avoided, as 
these drugs will interfere with the ability to make a diagnosis of lymphoma. 
There are no studies examining whether the survival times of cats with neoplasia 
associated with hypercalcaemia are worse than those without hypercalcaemia. 
 
Hypervitaminosis D 
Hypervitaminosis D refers to toxicity resulting from calcidiol and calcitriol as 
well as cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2). Iatrogenic 
causes include excessive dietary supplementation or excessive treatment. 
Certain plants such as Jessamine can contain glycosides of calcitriol and 
therefore, ingestion can lead to hypercalcaemia. Some rodenticides also contain 
cholecalciferol. Topical ointments for management of psoriasis can contain 
vitamin D analogues and possible exposure to such creams should be discussed 
with the owners. As these ointments contain vitamin D analogues, calcidiol or 
calcitriol concentrations will not generally be increased if measured. There is 
typically a parallel increase in calcium and phosphate concentration in patients 
with hypervitaminosis D. Calcidiol can be normal or increased depending on 
which form of vitamin D is associated with the intoxication. PTH concentration 
will be low due to hypercalcaemia and also the suppressive effects of calcitriol. 
Calcidiol can remain elevated for weeks to months following intoxication due to 
lipid storage and slow release. The decline of calcitriol is quicker. The presence 
of soft tissue calcification may be more suggestive of vitamin D toxicity than 
other causes of hypercalcaemia as both calcium and phosphate rise in parallel 
resulting in an increased calcium x phosphate product.  
 
Granulomatous disease 
Granulomatous inflammation is a potential but uncommon cause of 
hypercalcaemia in cats. Hypercalcaemia can result from granulomatous 
inflammation because macrophages can synthesise calcitriol from calcidiol 
without negative feedback regulation. Therefore calcitriol concentrations can be 
high and calcidiol concentrations normal. Hypercalcaemia has been associated 
with mycobacteria32, feline infectious peritonitis (FIP)14, Toxoplasmosis14, 
Nocardia32, Cryptococcus14 and Actinomyces rhintitis14 in cats. It may be difficult 
to distinguish between hypercalcaemia associated with granulomatous disease 
and neoplasia if abnormalities are found on physical examination or imaging. 
Increased calcitriol concentration may be helpful; however, a definitive diagnosis 
should be based on cytological or histopathological examination of tissue. 
 
Hypoadrenocorticism 
Hypoadrenocorticism (Addison’s) is much less common in cats compared to 
dogs. The mechanism by which hypercalcaemia develops is poorly understood. It 
may be associated with increased renal reabsorption of calcium secondary to 
hypovolaemia, the presence of a metabolic acidosis or due to increased bone 
resorption. The hypercalcaemia resolves with successful management of 
hypoadrenocorticism. Standard treatment generally involves the use of 
fludrocortisone +/- prednisolone. 
 
Case studies 
 
 
 
Case study 1 
Luna and Apollo, 5mth FE and MN BSH presented with a one-week history of 
lethargy, inappetance and a four-day history of PU/PD. Both kittens lived indoors 
in the same household and had no access to vitamin D containing rodenticides or 
psoriasis ointments. Both kittens were fed a variety of complete wet and dry 
foods and were supplemented with a complementary natural wet food. Physical 
examination findings were unremarkable. Table 1 presents the biochemical 
findings at the initial visit. The kittens were non-azotaemic and the only 
significant finding was a marked total hypercalcaemia. The USG for Apollo was 
1.033 and for Luna was 1.012. Calcium oxalate crystalluria was seen on sediment 
exam in both kittens. Abdominal and thoracic imaging was unremarkable. 
 
Table 1: Biochemical findings at the initial visit.  
 
 Apollo Luna Reference interval 
Creatinine (µmol/l) 123.0 106.0 133 – 175 
Urea (mmol/l) 7.0 6.6 6.5 – 10.5 
Phosphorous (mmol/l) 1.34 1.20 0.95 – 1.55 
Total calcium 
(mmol/l) 
>4.00 >4.00 2.30 – 2.50 
Albumin (g/l) 27.1 28.5 24.0 – 35.0 
Globulins (g/l) 41.1 41.2 21.0 – 51.0 
Total protein (g/l) 79.9 85.0 77.0 – 91.0 
Sodium (mmol/l) 153.0 146.0 145.0 – 157.0 
Potassium (mmol/l) 4.7 4.27 3.50 – 5.50 
Chloride (mmol/l) 120.0 121.0 100 – 124.0 
ALT activity (IU/l) 37.0 33.0 15.0 – 45.0 
ALKP activity (IU/l) 48.0 52.0 15.0 – 60.0 
Total bilirubin (µmol/l) 0.6 3.5 0.0 – 10.0 
Cholesterol (mmol/l) 3.9 3.6 3.0 – 6.9 
 
Ionised calcium, vitamin D metabolites and PTH were measured (see Table 2). 
The ionised calcium measurement confirmed hypercalcaemia. Both calcitriol and 
calcidiol were increased in both kittens. PTH was low as would be expected in a 
patient with hypercalcaemia. PTH-rp was not measured due to the limited 
suspicion of neoplasia.   
 
Table 2: Ionised calcium, vitamin D metabolites and PTH concentrations 
 
 Apollo Luna Reference interval 
Ionised calcium (mmol/l) 1.82 1.83 1.10 – 1.40 
Calcitriol (pmol/l)  436 406 192 - 317 
Calcidiol (nmol/l) 553 243 126 - 163 
PTH (pmol/l) <0.22 <0.22 0.22 – 1.42 
 
Interpretation of results 
Both kittens had a total and ionised hypercalcaemia, normal phosphate 
concentration, increased calcitriol and calcidiol concentrations and low PTH 
concentration. This excluded parathyroid dependent causes of hypercalcaemia. 
The primary differential was hypervitaminosis D, although phosphate 
concentrations were normal. Iatrogenic hypercalcaemia, malignancy associated 
hypercalcaemia and granulomatous diseases seemed unlikely based on the 
normal imaging findings and the increased vitamin D metabolite concentrations.  
 
A dietary cause of the hypervitaminosis D was suspected and therefore food 
analysis was performed (see Table 3). Analysis of one of the diets (a natural 
complementary cat food) being fed to the kittens revealed excessive levels of 
both vitamin D3 (cholecalciferol) and D2 (ergocalciferol). The levels were 
approximately 10 times the nutritional maximum. 
 
Table 3: Dietary analysis of on of the foods being fed to the kittens.  
 
 Original 
food (wet 
weight 
fed) 
Dry 
matter 
(DM) 
Minimum 
requirement 
(DM) 
Nutritional 
maximum not 
associated with 
harmful effects 
(DM) 
Vitamin D3 
(IU/kg) 
53500 318325 750 (total 
Vitamin D3 and 
D2 combined) 
30000 (total 
Vitamin D3 and 
D2 combined) 
Vitamin D2 
(IU/kg) 
14500 86275 
Calcium (g/kg) 0.058 0.345 10 - 
Phosphate 
(g/kg) 
0.835 4.968 8.4 - 
Calcium: 
phosphorus 
ratio 
0.07:1 0.07:1 1:1 1.5: 1 
 
Ongoing management 
Both kittens were managed initially with IVFT 0.9% NaCl, furosemide and 
prednisolone. Diet was changed to a complete commercially available wet kitten 
food. Supplementation with psyllium husks was also recommended. IVFT and 
furosemide was discontinued after 5 days. Normocalcaemia was achieved in 5 
days in Luna and 22 days in Apollo. The prednisolone was gradually tapered and 
discontinued after normocalcaemia was achieved. The kittens both continued to 
do well and remained normocalcaemic and non-azotaemic for 1-year follow-up. 
 
Case study 2 
Flossie, 2yr FN DSH presented with a one-month history of weight loss and 
polydipsia. More recently, she returned home after being missing for five days 
and was non-ambulatory on her hind limbs. On general physical examination, 
she was in decreased body condition but was otherwise unremarkable. On 
neurological examination she was paraparetic. She had bilateral proprioceptive 
deficits in her hind limbs (paw placement and hopping) and lower motor 
neurone and cranial nerve function testing was normal. Neurolocalisation was 
T3 to L3. Initial haematology and biochemistry are presented in Table 4 and 5. 
The haematology revealed a left shift with increased band neutrophils 
suggesting inflammation. Biochemistry revealed a total hypercalcaemia and an 
increase in the muscle markers AST and CK. Urinalysis revealed good urine 
concentrating ability (1.043). Struvite crystals were noted on sediment 
examination. Ionised calcium was measured and confirmed the hypercalcaemia 
(1.77mmol/l). FIV/FeLV testing was negative. 
 
Table 4: Haematology results at initial presentation 
 
  Reference interval 
Hb 11.70 8.00 – 15.00 g/dl 
Hct  37.3 25.0 – 45.0 % 
MCV 53.2 40.0 – 55.0 fl 
MCH 16.8 12.5 – 17.0 pg  
MCHC 31.5 30.0 – 35.0 g/dl  
Platelets 333 200 – 700 x 109/l 
WBC 16.90 4.90 – 19.0 x 109/l 
Band neutrophils 0.85 0.0 0 – 0.30 x 109/l 
Segmented neutrophils 10.99 2.40 – 12.50 x 109/l 
Lymphocytes 3.89 1.40 – 6.00 x 109/l 
Monocytes 0.51 0.10 – 0.70 x 109/l 
Eosinophils 0.68 0.10 – 1.60 x 109/l 
Basophils 0.00 0.00 – 0.10 x 109/l 
 
Table 5: Biochemistry results at initial presentation 
 
  Reference interval 
Creatinine (µmol/l) 71 133 – 175 
Urea (mmol/l) 6.3 6.5 – 10.5 
Phosphorous (mmol/l) 1.15 0.95 – 1.55 
Total calcium (mmol/l) 3.26 2.30 – 2.50 
Albumin (g/l) 27.5 24.0 – 35.0 
Globulins (g/l) 43.5 21.0 – 51.0 
Total protein (g/l) 71.0 77.0 – 91.0 
ALT activity (IU/l) 46.0 15.0 – 45.0 
ALKP activity (IU/l) 18.0 15.0 – 60.0 
Total bilirubin (µmol/l) 6.8 0.0 – 10.0 
Cholesterol (mmol/l) 2.9 3.0 – 6.9 
AST (IU/l) 71 0 – 20 
CK (IU/l) 3539 50 – 150 
 
On the morning following admittance to the hospital, an approximately 5cm 
discharging wound appeared over the right lumbar musculature. The area was 
clipped extensively and there was evidence of local skin necrosis. Cytological 
examination of fine needle aspirates of the wound was consistent with septic 
neutrophilic inflammation with moderate numbers of bacteria noted. Ziehl-
Neelsen staining was performed and there was no evidence of acid-fast 
organisms making Mycobacterium species unlikely. An MRI of the thoracolumbar 
spine was performed (see Figure 1). There was an extensive heterogenous lesion 
extending from T2 to L7 indicated by the arrow on figure 1. The lesion extended 
superficially and deep to invade the intervertebral foraminae at T13 to L1 
resulting in spinal cord compression. Abdominal ultrasound was unremarkable. 
 
Figure 1: Dorsal MR imaging of the thoracolumbar spine. Arrows indicate the 
extensive heterogenous lesion that was identified. 
 
 
A surgical biopsy of the lumbar musculature was obtained and submitted for 
histopathology. The findings were consistent with pyogranulomatous 
inflammation. Bacterial culture and sensitivity revealed a moderate growth of 
mixed anaerobes that was sensitive to metronidazole. Toxoplasma serology and 
Mycobacterium species PCR were negative. 
 
Interpretation of results 
Prior to the histopathology results, the primary differential was granulomatous 
disease, however, malignancy associated hypercalcaemia could not be fully 
excluded. The histopathology confirmed severe extensive paraspinal chronic 
pyogranulomatous inflammation that was resulting in empyema and 
hypercalcaemia. The initial cause of this may have been penetrating trauma such 
as a cat bite or foreign body. The empyema was considered to be the cause of the 
hind limb paraparesis. The pyogranulomatous inflammation was considered to 
be causing the hypercalcaemia as a result of calcitriol production by 
macrophages although calcitriol was not measured.  
 
Ongoing management 
Flossie was managed with IVFT (0.9% NaCl) and antibiotic therapy and 
demonstrated a rapid and progressive clinical improvement. The paraparesis 
fully resolved within 5 days and the hypercalcaemia within 7 days. Given the 
rapid clinical improvement in response to this therapy, further investigations 
into hypercalcaemia such as measurement of PTH, PTH-rp and vitamin D 
metabolites were not pursued. Flossie was continuing to do well at a 6 month 
recheck. 
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